Vicus Capital Sells 1,363 Shares of Pfizer Inc. $PFE

Vicus Capital reduced its position in Pfizer Inc. (NYSE:PFE) by 11.7% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 10,276 shares of the biopharmaceutical company’s stock after selling 1,363 shares during the period. Vicus Capital’s holdings in Pfizer were worth $249,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in PFE. Capital Advisory Group Advisory Services LLC raised its position in Pfizer by 2.9% in the 2nd quarter. Capital Advisory Group Advisory Services LLC now owns 13,542 shares of the biopharmaceutical company’s stock worth $328,000 after buying an additional 388 shares during the last quarter. Trust Co of the South grew its stake in shares of Pfizer by 1.5% in the second quarter. Trust Co of the South now owns 29,386 shares of the biopharmaceutical company’s stock worth $712,000 after acquiring an additional 441 shares during the period. Charter Oak Capital Management LLC raised its holdings in shares of Pfizer by 4.3% during the second quarter. Charter Oak Capital Management LLC now owns 10,663 shares of the biopharmaceutical company’s stock valued at $258,000 after purchasing an additional 444 shares during the last quarter. Ballentine Partners LLC lifted its position in Pfizer by 0.5% during the second quarter. Ballentine Partners LLC now owns 93,228 shares of the biopharmaceutical company’s stock valued at $2,260,000 after purchasing an additional 458 shares during the period. Finally, Members Trust Co boosted its holdings in Pfizer by 2.1% in the first quarter. Members Trust Co now owns 23,175 shares of the biopharmaceutical company’s stock worth $587,000 after purchasing an additional 467 shares during the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

PFE has been the subject of a number of research reports. Morgan Stanley boosted their target price on shares of Pfizer from $32.00 to $33.00 and gave the company an “equal weight” rating in a research note on Wednesday, August 6th. Citigroup lifted their price objective on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. UBS Group reissued a “neutral” rating and issued a $28.00 target price on shares of Pfizer in a report on Wednesday. Wall Street Zen downgraded Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday, September 28th. Finally, Bank of America increased their price objective on shares of Pfizer from $27.00 to $28.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 6th. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $28.29.

Pfizer Stock Performance

NYSE:PFE opened at $27.08 on Friday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The stock has a 50-day simple moving average of $24.62 and a two-hundred day simple moving average of $24.14. The firm has a market capitalization of $153.94 billion, a PE ratio of 14.40, a P/E/G ratio of 0.88 and a beta of 0.55. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $30.43.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. During the same quarter last year, the company earned $0.60 earnings per share. The business’s revenue for the quarter was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.